Moreover, while our findings offer insight into how bDMARD treatment affects CD4+ T cell subtypes in the blood, they do not account for the potential treatment effects on joint-resident T cells which play a critical role in the initiation and progression of joint inflammation in RA. This evidence concerns the gene CD4 and rheumatoid arthritis.